As yet, there exists no consensus as to whether proactive or reactive monitoring is the most appropriate approach in patients with inflammatory bowel disease (IBD) who receive infliximab therapy.
In therapeutic drug monitoring (TDM), measurements of trough levels can be used to guide adjustments of treatment intensity as a way to minimize the risk of treatment failure. In some cases, patients are monitored proactively; in other cases, patients are monitored reactively, or only when they report signs or symptoms that may point to a loss of response to a drug. As yet, there exists no consensus as to whether proactive or reactive TDM is the most appropriate approach in patients with inflammatory bowel disease (IBD) who receive infliximab therapy.
Some research has pointed to the superiority of proactive TDM; one recent study from Portugal in 205 patients with IBD, 56 of whom received proactive monitoring, showed that those who were proactively monitored received more treatment escalation, needed fewer surgeries, and had higher rates of mucosal healing than their counterparts who received reactive monitoring.1
However, in somewhat contrasting findings, researchers from Spain reported in a new study that in the first year of treatment with biosimilar infliximab CT-P13 (Inflectra, Remsima), patients with IBD did not have improved response or remission rates with the use of proactive monitoring versus reactive monitoring.2
In the study, 77 patients with IBD, 23 of whom had ulcerative colitis and 54 of whom had Crohn disease, received either proactive monitoring (n = 41) or reactive monitoring (n = 36). All of these patients were starting treatment with CT-P13.
The proactive monitoring group had levels of infliximab and antidrug antibodies measured at week 14, and those patients whose drug levels were too low received intensification, regardless of their clinical response to infliximab.
At week 14, 58.5% of the proactive monitoring group and 63.9% of the reactive monitoring group had achieved clinical remission. In the 2 groups respectively, 80.5% and 80.6%, respectively, had at least a partial response. At week 54, 61.0% of the proactive monitoring group and 77.8% of the reactively monitoring group were in clinical remission, and 73.2% and 80.6%, respectively, had at least a partial response.
Of the 13 patients in the proactive group who had their treatment intensified, there were no significant differences observed versus the reactive monitoring group in terms of secondary loss of response to infliximab.
According to the authors, proactive management does not improve response or remission rates for patients receiving CT-P13 in the first year versus reactive monitoring, and treatment intensification does not appear to prevent secondary loss of response in the first year of therapy.
References
1. Fernandes SR, Bernardo S, Simões C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease [published online June 27, 2019]. Inflamm Bowel Dis. doi: 10.1093/ibd/izz131.
2. González AE, Segura PS, Lara DO, et al. Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease [published online November 27, 2019]. Med Clin (Barc). doi: 10.1016/j.medcli.2019.07.025.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.